Australia markets open in 2 hours 19 minutes
  • ALL ORDS

    7,225.20
    -27.10 (-0.37%)
     
  • AUD/USD

    0.7625
    +0.0002 (+0.03%)
     
  • ASX 200

    6,974.00
    -21.20 (-0.30%)
     
  • OIL

    59.63
    +0.31 (+0.52%)
     
  • GOLD

    1,732.60
    -12.20 (-0.70%)
     
  • BTC-AUD

    78,747.45
    -187.26 (-0.24%)
     
  • CMC Crypto 200

    1,286.57
    -8.02 (-0.62%)
     

Bluechiip Ltd (BCT.AX) Receives $1.62 million R Tax Incentive Refund

·3-min read
Bluechiip Ltd
Bluechiip Ltd

Bluechiip Ltd (BCT.AX) Receives $1.62 million R&D Tax Incentive Refund

Melbourne, Australia, Mar 15, 2021 - (ABN Newswire) - Bluechiip Limited (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced that it has received $1.62M Research and Development Tax Incentive Refund from the Australian Tax Office for the financial year ended 30 June 2020.

Andrew McLellan, Bluechiip Limited's Managing Director, welcomed the refund and said it would provide a significant cash injection for the Company, on top of Bluechiip's reported cash balance as at 31 December 2020 of $5.61M.

"The $1.62M is significantly more than the $1.23M we received for the financial year ended 2019 and is above our expectations of $1.50M, which we reported as a provision in our 30 June 2020 accounts," he said.

He said the refund was in line with Bluechiip's increased R&D activity during the 2019/20 financial year, which focused on improving its core chip technology's scale and efficiency.

"We now have the capability to manufacture 5-10 million Bluechiip chips per year in multiple formats for different market needs. We are well positioned to supply at scale as we continue to progress our negotiations with original equipment manufacturers (OEMs) and bring our own line of Bluechiip Enabled consumables to the global bio-preservation market."


About Bluechiip Ltd:


Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at http://www.bluechiip.com

Contact:

Lee Mitchell
Company Secretary
Bluechiip Limited
E: leem@nrlawyers.com.au
T: +61 (0) 3 9640 0400

Source:
Bluechiip Ltd

Copyright (C) 2021 ABN Newswire. All rights reserved.